Your browser doesn't support javascript.
loading
Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.
O'Leary, Rebecca L; Duijm, Lucien E M; Boersma, Liesbeth J; van der Sangen, Maurice J C; de Munck, Linda; Wesseling, Jelle; Schipper, Robert-Jan; Voogd, Adri C.
Afiliação
  • O'Leary RL; Department of Epidemiology, Maastricht University, Maastricht, Netherlands.
  • Duijm LEM; Department of Radiology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.
  • Boersma LJ; Department of Radiation Oncology (Maastro), GROW-School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, Netherlands.
  • van der Sangen MJC; Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands.
  • de Munck L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
  • Wesseling J; Division of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Schipper RJ; Department of Pathology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Voogd AC; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
Br J Cancer ; 2024 Jul 09.
Article em En | MEDLINE | ID: mdl-38982194
ABSTRACT

BACKGROUND:

The first aim of this study was to examine trends in the risk of ipsilateral invasive breast cancer (iIBC) after breast-conserving surgery (BCS) of ductal carcinoma in situ (DCIS). A second aim was to analyse the association between DCIS grade and the risk of iIBC following BCS. PATIENTS AND

METHODS:

In this population-based, retrospective cohort study, the Netherlands Cancer Registry collected information on 25,719 women with DCIS diagnosed in the period 1989-2021 who underwent BCS. Of these 19,034 received adjuvant radiotherapy (RT). Kaplan-Meier analyses and Cox regression models were used.

RESULTS:

A total of 1135 patients experienced iIBC. Ten-year cumulative incidence rates of iIBC for patients diagnosed in the periods 1989-1998, 1999-2008 and 2009-2021 undergoing BCS without RT, were 12.6%, 9.0% and 5.0% (P < 0.001), respectively. For those undergoing BCS with RT these figures were 5.7%, 3.7% and 2.2%, respectively (P < 0.001). In the multivariable analyses, DCIS grade was not associated with the risk of iIBC.

CONCLUSION:

Since 1989 the risk of iIBC has decreased substantially and has become even lower than the risk of invasive contralateral breast cancer. No significant association of DCIS grade with iIBC was found, stressing the need for more powerful prognostic factors to guide the treatment of DCIS.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Br J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Br J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda